Management and Outcomes for Long-Segment Hirschsprung Disease: A Systematic Review from the APSA Outcomes and Evidence Based Practice Committee

Space: StayCurrentMD Author: Akemi L. Kawaguchi, Yigit S. Guner, Stig Sømme, Alexandria C. Quesenberry, L. Grier Arthur, Juan E. Sola, Cynthia D. Downard, Rebecca M. Rentea, Patricia A. Valusek, Caitlin A. Smith, Mark B. Slidell, Robert L. Ricca, Roshni Dasgupta, Elizabeth Renaud, Do Published: 2021-03-28

Author / Expert

Akemi L. Kawaguchi, Yigit S. Guner, Stig Sømme, Alexandria C. Quesenberry, L. Grier Arthur, Juan E. Sola, Cynthia D. Downard, Rebecca M. Rentea, Patricia A. Valusek, Caitlin A. Smith, Mark B. Slidell, Robert L. Ricca, Roshni Dasgupta, Elizabeth Renaud, Do

Topic overview

Abstract

Objective

: Long-Segment Hirschsprung Disease (LSHD) differs clinically from short-segment disease. This review article critically appraises current literature on the definition, management, outcomes, and novel therapies for patients with LSHD.

Methods

: Four questions regarding the definition, management, and outcomes of patients with LSHD were generated. English-language articles published between 1990 and 2018 were compiled by searching PubMed, Scopus, Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar. A qualitative synthesis was performed.

Results

: 66 manuscripts were included in this systematic review. Standardized nomenclature and preoperative evaluation for LSHD are recommended. Insufficient evidence exists to recommend a single method for the surgical repair of LSHD. Patients with LSHD may have increased long-term gastrointestinal symptoms, including Hirschsprung-associated enterocolitis (HAEC), but have a quality of life similar to matched controls. There are few surgical technical innovations focused on this disorder.

Conclusions

: A standardized definition of LSHD is recommended that emphasizes the precise anatomic location of aganglionosis. Prospective studies comparing operative options and long-term outcomes are needed. Translational approaches, such as stem cell therapy, may be promising in the future for the treatment of long-segment Hirschsprung disease.